Foghorn Therapeutics Sees Increase Amid High Trading Volume

2 min read | September 16, 2024 03:47 AM PDT | By Team Kalkine Media

Google News:

Foghorn Therapeutics Sees Increase Amid High Trading Volume — Image source: Shutterstock

Recent News

Why AbbVie (NYSE:ABBV) Gains in S&P 500 Index Biopharma Push?

Why FactSet Research Systems Anchors Index Stability Gains Now?

Why Is M&T Bank Driving S&P 500 Index Regional Banking Strength?

Why Is MPLX Expanding Midstream Across NYSE Composite Energy?

Make Kalkine Media
My Trusted Source

In the Healthcare sector, Foghorn Therapeutics Inc. experienced a 9.5% increase in its share price, closing at $9.72 during the last trading session. This rise was accompanied by a significant increase in trading volume compared to typical sessions. Over the past four weeks, the stock has risen 43.2%.

Strong Financial Results and Pipeline Progress

The recent uptick in Foghorn Therapeutics (NASDAQ:FHTX) stock can be linked to the company’s robust financial results for the second quarter of 2024 and positive developments in its pipeline candidates for oncology treatments. The company has reported progress in its studies, which may have contributed to the recent share price increase.

Quarterly Loss and Revenue Expectations

For the upcoming quarterly report, Foghorn Therapeutics is projected to report a loss of $0.41 per share, reflecting a year-over-year decrease of -20.6%. Revenue is expected to be $7.01 million, down 59.9% compared to the same quarter last year.

Trends in Earnings Estimates

Earnings estimate revisions can often influence stock price movements. For Foghorn Therapeutics, the consensus EPS estimate for the upcoming quarter has been revised 7% lower over the past 30 days. Typically, a downward trend in earnings estimates does not correlate with sustained stock price increases. Observers will be watching to see if the recent share price boost can be maintained.

Industry Comparison

In the same sector, United Therapeutics (NASDAQ:UTHR) closed the last trading session 0.6% lower at $339.12. Over the past month, United Therapeutics has experienced a 5.6% return.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.